AR031074A1 - Una composicion farmaceutica que comprende un derivado de benzamida como ingrediente activo - Google Patents

Una composicion farmaceutica que comprende un derivado de benzamida como ingrediente activo

Info

Publication number
AR031074A1
AR031074A1 ARP000104212A ARP000104212A AR031074A1 AR 031074 A1 AR031074 A1 AR 031074A1 AR P000104212 A ARP000104212 A AR P000104212A AR P000104212 A ARP000104212 A AR P000104212A AR 031074 A1 AR031074 A1 AR 031074A1
Authority
AR
Argentina
Prior art keywords
benzamide derivative
pharmaceutical composition
formulations
additives
mixing
Prior art date
Application number
ARP000104212A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR031074A1 publication Critical patent/AR031074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica que comprende un derivado de benzamida representado por la formula (1) donde A representa una estructura ilustrada por cualquiera de las siguientes formulas (2) o su sal farmacéuticamente aceptable, y uno o más de un aditivo, en que uno o más aditivos es seleccionado del grupo formado por un excipiente, un desintegrante, un aglutinante, un lubricante, un agente para revestimiento y un solvente. Se pueden obtener formulaciones farmacéuticas estables mezclando un derivado de benzamida farmacéuticamente util o su sal farmacéuticamente aceptable con aditivos que no producen fácilmente productos de degradacion, mezclando una sal de ácido orgánico, un compuesto de amina, y una sustancia básica inorgánica, produciendo formulaciones solidas por medio del método de granulacion en seco, y además ajustando el pH de las formulaciones líquidas a un rango entre 4 y 12. Se pueden obtener formulaciones farmacéuticas que producen pocos productos de la degradacion y que son lo suficientemente aceptables como para ser usadas por drogas medicinales.
ARP000104212A 1999-08-16 2000-08-15 Una composicion farmaceutica que comprende un derivado de benzamida como ingrediente activo AR031074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22955199A JP2001064177A (ja) 1999-08-16 1999-08-16 ベンズアミド誘導体を有効成分とする製剤

Publications (1)

Publication Number Publication Date
AR031074A1 true AR031074A1 (es) 2003-09-10

Family

ID=16893948

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104212A AR031074A1 (es) 1999-08-16 2000-08-15 Una composicion farmaceutica que comprende un derivado de benzamida como ingrediente activo

Country Status (29)

Country Link
EP (1) EP1207881B1 (es)
JP (2) JP2001064177A (es)
KR (1) KR100683876B1 (es)
CN (1) CN1205931C (es)
AR (1) AR031074A1 (es)
AU (1) AU780151B2 (es)
BG (1) BG65662B1 (es)
BR (1) BR0013283A (es)
CA (1) CA2380757C (es)
CY (1) CY1116273T1 (es)
CZ (1) CZ302924B6 (es)
DK (1) DK1207881T3 (es)
EE (1) EE05331B1 (es)
ES (1) ES2536705T3 (es)
HK (1) HK1046501B (es)
HR (1) HRP20020181B1 (es)
HU (1) HU230386B1 (es)
IL (1) IL148169A0 (es)
MX (1) MXPA02001575A (es)
NO (1) NO328957B1 (es)
NZ (1) NZ517356A (es)
PL (1) PL201388B1 (es)
PT (1) PT1207881E (es)
RU (1) RU2257206C2 (es)
SK (1) SK287547B6 (es)
TW (1) TWI245630B (es)
UA (1) UA73316C2 (es)
WO (1) WO2001012193A1 (es)
ZA (1) ZA200201466B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
AU2001288102A1 (en) * 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
EP1490013B1 (en) 2002-03-07 2010-02-17 University Of Delaware Methods for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising hydroxyurea
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
WO2008123395A1 (ja) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
KR101405615B1 (ko) * 2007-08-27 2014-06-12 (주)아모레퍼시픽 조성물 내 ｐＨ 조절을 통해 안정화된 벤즈아미드 화합물을함유하는 피부 외용제 조성물, 및 그 벤즈아미드 화합물안정화 방법
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
AU2009286982C1 (en) * 2008-08-29 2012-04-26 Bayer Intellectual Property Gmbh N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275)polymorph B
IN2014MN02116A (es) * 2013-04-04 2015-09-04 Daiichi Sankyo Companyltd
CN107405322B (zh) 2015-03-19 2020-08-18 第一三共株式会社 含有抗氧化剂的固体制剂
ES2821733T3 (es) 2015-03-19 2021-04-27 Daiichi Sankyo Co Ltd Preparación sólida que contiene colorante
CN111867559A (zh) * 2019-01-25 2020-10-30 株式会社爱茉莉太平洋 含有苯甲酰胺化合物以及增溶剂的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤

Also Published As

Publication number Publication date
EP1207881B1 (en) 2015-04-01
JP2003507330A (ja) 2003-02-25
NO20020774L (no) 2002-03-04
CY1116273T1 (el) 2017-02-08
NZ517356A (en) 2003-07-25
CZ302924B6 (cs) 2012-01-18
CN1370068A (zh) 2002-09-18
JP2001064177A (ja) 2001-03-13
MXPA02001575A (es) 2003-10-14
EE05331B1 (et) 2010-08-16
PL353449A1 (en) 2003-11-17
JP4854158B2 (ja) 2012-01-18
CN1205931C (zh) 2005-06-15
NO20020774D0 (no) 2002-02-15
ES2536705T3 (es) 2015-05-27
RU2257206C2 (ru) 2005-07-27
ZA200201466B (en) 2002-09-02
DK1207881T3 (da) 2015-06-22
KR100683876B1 (ko) 2007-02-15
UA73316C2 (uk) 2005-07-15
KR20020020815A (ko) 2002-03-15
CA2380757A1 (en) 2001-02-22
IL148169A0 (en) 2002-09-12
SK2092002A3 (en) 2002-07-02
HK1046501B (zh) 2005-09-30
AU6442700A (en) 2001-03-13
HU230386B1 (hu) 2016-03-29
HRP20020181A2 (en) 2005-10-31
EE200200073A (et) 2003-04-15
BG106516A (en) 2002-10-31
EP1207881A1 (en) 2002-05-29
AU780151B2 (en) 2005-03-03
PL201388B1 (pl) 2009-04-30
HUP0203226A3 (en) 2003-12-29
BR0013283A (pt) 2002-04-23
HRP20020181B1 (hr) 2016-01-29
SK287547B6 (sk) 2011-01-04
CA2380757C (en) 2009-01-27
HK1046501A1 (en) 2003-01-17
TWI245630B (en) 2005-12-21
WO2001012193A1 (en) 2001-02-22
CZ2002540A3 (cs) 2002-06-12
RU2002106815A (ru) 2004-01-27
PT1207881E (pt) 2015-06-05
NO328957B1 (no) 2010-06-28
HUP0203226A2 (hu) 2003-01-28
BG65662B1 (bg) 2009-05-29

Similar Documents

Publication Publication Date Title
ES2540853T3 (es) Sales de dicetopiperazina para la administración de fármacos
AR031074A1 (es) Una composicion farmaceutica que comprende un derivado de benzamida como ingrediente activo
GB1114069A (en) Benzimidazole derivatives and anthelmintic compositions containing them
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
KR950007850A (ko) 항균물질 및 항궤양물질 포함 제제
CA2696335C (en) Gel containing pirfenidone
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ATE409461T1 (de) Hfc lösungsformulierungen enthaltend ein anticholinergikum
DK1345611T3 (da) Antibiotisk/analgetisk formulering og en fremgangsmåde til fremstilling deraf
RS50360B (sr) Farmaceutske formulacije derivata platine
NO20030533D0 (no) Vandige farmasöytiske preparater
EA200702593A1 (ru) Высококонцентрированные композиции, применимые для борьбы с экто- и эндопаразитами
NZ548689A (en) Antiparasitic composition containing an organic amine salt of closantel
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
RS50123B (sr) Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
UY25864A1 (es) Derivados de acetamida antagonistas de receptor de nk1
ES2059471T3 (es) Un procedimiento para preparar un derivado de rodamina.
CA2436414A1 (en) Veterinary dermatologic composition
ES2037758T3 (es) Un metodo de uso de un derivado quinolincarboxilico y su procedimiento de preparacion.
TR200302027T4 (tr) Hayvanlarda görülen parazit kaynaklı hastalıkarın tedavisine yönelik ilaç kompozisyonları
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.

Legal Events

Date Code Title Description
FG Grant, registration